SM‑04554
Topical small molecule, a Wnt/β-catenin pathway ACTIVATOR (Samumed/Biosplice) for androgenetic alopecia. Regenerative (not antiandrogen) mechanism. INVESTIGATIONAL: phase 2 with MODEST/mixed results, not approved, development status uncertain.
WHAT IS SM-04554?
Detailed overview
SM-04554 (Samumed, now Biosplice Therapeutics) is a topical small molecule that ACTIVATES the Wnt/β-catenin pathway – a regenerative pathway that plays a key role in the development and cycling of the hair follicle. The idea is that stimulating the Wnt pathway could trigger the formation of new hair follicles and an increase in follicle density, which is a fundamentally different approach from DHT inhibition (antiandrogens) or improving perfusion (minoxidil). CLINICAL REALITY: in the phase 2 trial, hair count increased statistically at some doses compared with vehicle, but the MAGNITUDE of the effect was MODEST and not clearly robust, and the further development status is uncertain. SM-04554-specific, peer-reviewed, confirmatory efficacy publications are scarce; the Wnt-modulator class is covered in a review article (PMID 34128760). Overall: an interesting regenerative concept, but a CLINICALLY UNPROVEN, mixed-result, investigational agent.
Developer
Samumed / Biosplice Therapeutics
Status
INVESTIGATIONAL – phase 2 (modest/mixed result); not approved
Mechanism of action
Topical Wnt/β-catenin pathway activator (regenerative, NOT antiandrogen)
Evidence
Limited, mixed; no confirmatory phase 3
Access
Trial only; not available as a routine treatment
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 3
- Local scalp reaction: phase trials reported mild application-site reactions (redness, itching); generally well tolerated, but the full human safety picture is limited.
- Limited and mixed efficacy data: the phase 2 trial showed only MODEST, not clearly robust hair-count increases, and the further development status is uncertain; do not expect confirmed efficacy.
- Modulating the Wnt pathway is a theoretical consideration: the Wnt pathway is active in many tissues; for a local topical agent systemic effect is designed to be minimal, but long-term human safety is not fully characterized.
Contraindications · 3
- Not approved, investigational: no approved indication or dose; not available as a routine treatment.
- Pregnancy and breastfeeding: avoid due to lack of human data.
- Broken, inflamed scalp; known hypersensitivity to the active or the vehicle.
Related Hair & Skin
Same therapeutic category
Studies
Related research and clinical findings
Telegram
Have a question about SM‑04554?
Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.